Objective. The objective of this study was to identify predictors of response and remission to tocilizumab (TCZ) in RA patients seen in daily routine clinical practice.
Introduction
Tocilizumab (TCZ) is a humanized monoclonal antibody against the human IL-6 receptor that inhibits signalling via both soluble and membrane-bound human IL-6 receptors [1] . For RA patients, the drug was first developed in Japan, demonstrating a benefit on joint symptoms [24] as well a limitation of structural progression [5, 6] . TCZ has been approved in Europe [7] for the treatment of moderate to severe active RA in patients who have had an inadequate response to one or more DMARDs and/or TNF antagonists.
In the last 10 years, intensive studies on RA inflammation processes have led to the development of several biologic drugs (including TNF blockers, TCZ and rituximab), producing huge advancements in RA treatment. However, response to these therapies is heterogeneous, with roughly two-thirds of patients responding and one-third non-responding. Given the destructive nature of RA, the risk of adverse effects and the considerable costs of biologic therapy, there is a need to identify predictors of response before starting biotherapy. Some studies have suggested that high levels of RF and ACPA are associated with a better response to rituximab [8] . In contrast to B cell depletion, several studies have suggested that high levels of RF and/or ACPA are correlated with a decreased response to TNF blockade [9, 10] . However, despite 10 years of biologics use in RA treatment, there is no way to predict therapeutic response.
Therefore, identifying predictors of response to biologic therapies would improve care in selecting patients able to respond. These would also improve medical cost-effectiveness because they would decrease the number of nonresponding patients. We therefore conducted a retrospective study of the use of TCZ in patients with RA in five academic centres in France. We described the clinical profile of these patients from December 2009 to June 2011 and analysed potential predictive factors.
Patients and methods

Patients
Our cohort included 204 patients treated between December 2009 and June 2011 in five rheumatology departments in France (Besanç on, Dijon, Grenoble, Montpellier and Saint-É tienne). The patients all fulfilled the 1987 ACR criteria for RA [11] . The clinical and biological data were collected from medical records. TCZ was given every 4 weeks at a usual dose of 8 mg/kg and could be adapted according to the French or European recommendation authorities [12, 13] . At each visit the following parameters were recorded: tender joint count (TJC) and swollen joint count (SJC), 28-joint disease activity score (DAS28), patient global assessment (PGA), ESR, CRP, haemoglobin (Hb), white blood cell (WBC) count, neutrophil count, prednisone use and dose taken concomitantly, combination with DMARD use and dose taken (MTX, LEF, HCQ, SSZ and AZA]. Increased or decreased doses of prednisone and DMARD were possible, at the discretion of the referring physician. The study was approved by the local ethical committee (Comité de protection des personnes Sud Mediterrané e IV, Montpellier, France) in accordance with the Helsinki Declaration and informed consent was obtained from each patient.
Evaluation of clinical efficacy RA disease activity was assessed by the DAS28 score, taking into account ESR [14] . Response was evaluated using European League Against Rheumatism (EULAR) criteria [15] at different times: 1, 2, 3 and 6 months. We also evaluated the efficacy of TCZ on the number of patients in remission (DAS28-ESR <2.6) at 1, 2, 3 and 6 months of treatment.
Parameters associated with TCZ response or remission
We investigated putative predictive factors (clinical or laboratory) of remission and EULAR response at 6 months of treatment with TCZ. Several parameters that could be related to a better or a worse response were analysed: age, gender, current smokers, disease duration, prior cardiovascular disease (CVD), TCZ combination with DMARD or MTX, TCZ combination with steroids, baseline PGA, baseline SJC and TJC, baseline DAS28, presence of erosions, RF or ACPA positivity, baseline ESR and CRP levels, baseline blood parameters levels (Hb, WBC or neutrophils), biologic-naive patients vs previous failure of at least one biologic, early EULAR response or remission at 12 or 3 months, change in DAS28 >0.6, >1.2 points between baseline and 3 months of TCZ treatment and a change in neutrophil count between baseline and 1 month.
Statistical analysis
A comprehensive description of the sample was achieved by giving the frequencies of different categories for qualitative variables. Since the distributions of quantitative variables are not always Gaussian, they were described using the mean and standard deviation but also the median and minimum and maximum values.
The comparison between groups was performed using the Wilcoxon or Student's test depending on the distribution for quantitative variables and using the chi-square test for qualitative variables. When the conditions of validity of the chi-square test were not met, it was replaced by the Fisher's exact test.
A receiver operating characteristic (ROC) curve was used to determine the best threshold for age and CRP to predict the occurrence of EULAR response and remission at 6 months. An a priori threshold of a decrease of >25% in neutrophil count between initiation of TCZ and 1 month was determined by analysis of the literature (J. Saech, unpublished observation; Abstract 294, ACR 2010).
Multivariate analysis (logistic regression) was performed to highlight the respective influence of each covariate on the endpoint studied, i.e. EULAR response or remission. Variables significantly associated with the endpoint in the univariate analysis (P < 0.05) and a stepwise selection process was used to select the final model. When the hypothesis of an interaction between covariates was relevant, it was investigated. Adjusted ORs and 95% CIs were calculated. The significance level was set at 5% for all tests used. Statistical analysis was performed using SAS software version 9 (SAS Institute, Cary, NC, USA).
Results
Characteristics of patients
Baseline characteristics of 204 RA patients are summarized in Table 1 . Most patients were female (81.4%) with a mean age of 55.2 (13.8) years. The mean disease duration www.rheumatology.oxfordjournals.org was 15.9 (9.9) years. Current smoking was present in 22.2%. All patients had previously been treated with DMARD and only 26 patients (12.7%) were biologics naive. Before TCZ the mean number of previous DMARDs and biologics used was 3.28 (1.6) and 2.41 (1.5), respectively. At least one erosion was observed in most patients (81.6%). RF and ACPA were positive in 70.9% and 65.6% of patients, respectively. The mean DAS28 score was 5.14 (1.3). The majority of patients had DMARDs in combination with TCZ (68.4%), which in three-quarters of cases was MTX with a mean dose of 14.4 (4.0) mg/week. Steroids were used in 64.7% of patients with a mean dose of 9.2 (7.7) mg/day.
Clinical efficacy of TCZ
Clinical efficacy was assessed using DAS28-ESR and EULAR response. In Table 1 , the evolution of these parameters during treatment with TCZ is summarized after 3 and 6 months. Among the 39 patients who were lost of follow-up at 6 months, three categories are described: primary failure before 6 months (n = 11), adverse events requiring discontinuation of TCZ (n = 13) and missing data (n = 15).
After 6 months of treatment the DAS28 score decreased from 5.14 (1.3) to 2.85 (1.4) and EULAR response reached 86.1% (60% for good response and 26.1% for moderate response). At 6 months, low disease activity was observed in 66.5% of RA patients and 44.5% were in DAS28 remission. Among the non-responder patients at 3 months, a moderate and a good EULAR response were observed at 6 months in 22.2% and 36.1% of RA patients, respectively (see supplementary  Table S1 , available at Rheumatology Online). In the same way, in the absence of remission at 3 months, only 27.3% of patients achieved remission at 6 months. In contrast, 26.2% of patients in remission at 3 months were no longer in remission at 6 months (see supplementary Table S2 , available at Rheumatology Online).
We then investigated the effect of DMARDs associated with TCZ. At 6 months, 49.5% of patients were using DMARDs and only 38.5% were still on MTX, with a mean dose of 12.6 (5.1) mg/week (Table 1 ). This dose was significantly decreased at 6 months (À1.156 mg, P < 0.01). EULAR response was similar in both groups at 3 months, while a trend was observed towards more remission or EULAR response with DMARDs (P = 0.09) at 6 months (Fig. 1A) . The efficacy of TCZ was also compared in biologics-naïve patients and those who failed one or more biologic therapies (mainly TNF antagonist drugs). No significant difference in EULAR response at 3 or 6 months was observed between the two groups of patients (Fig. 1B) . At 6 months, EULAR response was not associated with baseline DAS28 score ( Fig. 2A) , even if there was a tendency to get a better response in patients with baseline DAS28 >3.2 (87.5% of EULAR response) than in patients with a DAS28 <3.2 (69.2%, P = 0.09). In contrast, a high baseline level of disease activity (DAS28 >5.1 or >3.2) was significantly associated with a lower rate of EULAR remission (DAS28 <2.6) at 6 months (Fig. 2B) .
Predictors of EULAR response at 6 months
Univariate analysis and multivariate logistic regression were performed to identify predictors of EULAR response (good or moderate) vs non-response. We did not observe any correlation with disease duration, smoking, gender, RF or ACPA positivity, combination with MTX or another DMARD and failure of previous biotherapy (Table 2) . A decrease of >25% in neutrophil count after 1 month was not significantly associated with a better EULAR response at 6 months ( Table 2) .
A younger age, a high baseline PGA, the absence of significant CVD history before TCZ and an early EULAR response at 12 or 3 months were significantly associated with EULAR response at 6 months ( Table 2) . We searched thresholds associated with the response and we showed that age <55 years, baseline CRP >10 mg/l, a change in DAS28 of at least 0.6 or at least 1.2 between the start of TCZ and 3 months were significantly associated with EULAR response at 6 months ( Table 2) .
In multivariate analysis (Table 2) , only young age (<55 years), a high baseline CRP >10 mg/l and no history of CVD were associated with EULAR response at 6 months.
Predictors of remission at 6 months An early age and lower baseline scores of TJC, PGA and DAS28 were significantly associated with EULAR remission at 6 months. Early EULAR remission (at 12 or 3 months) was also correlated with remission (Table 3) . We found no thresholds significantly related to remission. In multivariate analysis (Table 3) , only a younger age was associated with DAS28 remission at 6 months.
Discussion
Since its launch in Europe, few data have been available on the use of TCZ in daily care of RA. Recently the German TAMARA (Tocilizumab and DMARDs: Achievement in Rheumatoid Arthritis) study [16] confirmed the efficacy of TCZ in daily practice. It was an open-label study of 286 subjects with a DAS of at least 3.2. At 6 months, 47.6% of patients reached DAS28 remission and 54.9% could be considered good EULAR responders. Our study confirmed the good efficacy and safety of TCZ treatment in real-life practice by achieving a remission rate of 44.5% and a EULAR response rate of 86% (60% is a good response). The high rate of remission is not only related to the biological effect of TCZ, as we have clearly demonstrated progressive improvement of the joint parameters and patient global health assessment. www.rheumatology.oxfordjournals.org ACT-SURE [22] observational study. In the DANBIO registry [23] , the authors reported that a high baseline DAS28 was correlated with a better response since these patients more often reached low disease activity (DAS28 <3.2). However, we did not highlight this difference as was previously described [17] .
In addition, identifying predictors of response is now a crucial therapeutic strategy in RA. In some studies on TNF antagonist [9, 10, 24] , cigarette smoking, female sex, a greater number of previously failed biologics and RF or ACPA positivity were correlated with a lower response. These parameters were not associated with response or remission with TCZ therapy. Interestingly, we suggest that an age <55 years, a high baseline CRP and no history of CVD are associated with a better TCZ response. Young age also seems predictive of remission. In patients with anti-TNF-a therapy, a number of clinical factors have been positively associated with treatment response, including younger age at therapy onset [25] . Elderly subjects tend to have somewhat less robust responses to etanercept than younger subjects [26] . In contrast to the TAMARA study [16] , the REACTION (REtrospective ACTemra Investigation for Optimal Needs of RA) study had already suggested that younger age was associated with a good EULAR response [21] . Our results support this association whatever the level of EULAR response.
In systemic JIA, TCZ is particularly effective due to its action on inflammatory markers [27, 28] . We suggest that the response to TCZ is more common in inflammatory RA having a high baseline CRP. Our results underline the importance of monitoring CRP levels under TCZ, as shown by two recent Japanese studies where the normalization of CRP at 3 months was predictive of improved remission [29, 30] .
We considered as previous CVD only patients with a past history of arterial hypertension, ischaemic heart disease, stroke or arteritis. Smoking patients, diabetes mellitus or dyslipidaemia were not included in this definition. Surprisingly, a history of CVD is associated with a poorer response. We have no convincing evidence to argue this result without the presence of more frequent drug interactions (statins, etc.) in the case of CVDs, which could explain a decrease in TCZ efficacy. However, we failed to provide data to illustrate this. Approximately 2030% of the subjects included in the registers receive biologic drugs without MTX [31] . In patients with anti-TNF-a therapy, response rates are significantly higher among patients who received anti-TNF-a therapies in combination with MTX or other DMARDs [13] . It seems that the use of a DMARD is predictive of a better response to anti-TNF-a. Our study highlights the efficacy of TCZ in monotherapy. Unlike previous studies [16, 21, 23] , we report no difference in efficacy when comparing our two groups of patients with and without DMARDs. This was previously suggested by the STREAM study [32] as well as the ACT-RAY [actemra (tocilizumab) radiographic] controlled study [33] , where no clinically relevant superiority of TCZ + MTX was observed over the switch to TCZ monotherapy strategy. Meaningful clinical and radiographic responses were achieved with both strategies, suggesting that TCZ monotherapy might be a valuable treatment strategy in suitable RA patients. Even if the characteristics of patients at baseline seemed to be similar between groups (see supplementary Table S3 , available at Rheumatology Online), it should be noted that the dose of MTX was significantly decreased during our study, but this difference appears to be not clinically relevant. These results should be analysed with caution due to the heterogeneity of the RA population explored. It should be remembered that according to the EULAR guidelines [13] , a DMARD (including MTX) in combination with a biotherapy is the reference treatment.
Our study comparing biologic-naive patients with patients who failed at least two biologic therapies (TNF antagonist, rituximab, abatacept or anakinra) showed no difference in response between these two groups of patients, similar to the Japanese REACTION study [21] . In the European population (e.g. the ACT-SURE or TAMARA studies) [16, 22] , patients without previous TNF inhibitor exposure experienced better efficacy than those previously treated with drugs from this class, possibly because of less severe, less refractory disease at study entry. Except for more frequent use of MTX among patients naive to biologics, the features were similar between the two groups (see supplementary Table S3 , available at Rheumatology Online). However, further studies are needed because the number of patients in our study who were naïve to anti-TNF agents was very low, thus we cannot exclude a lack of power in the interpretation of these results. The current study does have several limitations, mainly related to the methodology. We previously discussed the lack of power concerning interpretation of the results in biologic-naive patients. Further prospective studies seem necessary to evaluate the response to TCZ in patients refractory to at least two different biologic drugs. Retrospective analysis is still very interesting because it allows us to focus on clinical practice, but the retrospective collection has resulted in missing data. However, we had few important baseline data (CRP, DAS28 or cardiologic background) missing and few patients without follow-up. Confounding by indication and observation bias cannot be excluded from this study. However, at present there is scant knowledge about the predictors of TCZ response in the observational setting, thus giving no obvious reason for biasing recordings of patients with certain characteristics at 3 or 6 months of follow-up. Broader analyses on a larger sample of patients are now needed to confirm our results.
In conclusion, in our observational cohort of 204 patients followed in real life, we did not find additional effectiveness when TCZ was used in combination with DMARDs or when patients were naive to biologic agents. Most of our patients failed several biologic treatments (average 2.45). Our results are therefore hard to extrapolate to patients naive to biologic agents. We identified three predictors of a better response with TCZ: young age, high baseline CRP level and no history of CVD. We suggest that offering TCZ to young patients without previous CVDs and CRP >10 mg/l provides greater effectiveness and thus lower rates of primary failure. Our study is original because it reveals for the first time independent factors associated with a better response or remission with TCZ in RA. Other criteria have been described previously with other agents (RF or ACPA positivity for rituximab, younger age for anti-TNF-a drugs). These predictors of response are really helpful because they allow physicians to provide personalized treatment of the patient by selecting the biologic agent most suitable for the individual patient profile. However, we need to validate these results with different biologic agents (abatacept, rituximab or anti-TNF-a drugs) to assess their specificity for TCZ.
Rheumatology key messages
. Age, CRP and cardiovascular history seem predictive of response in RA patients treated with TCZ. . Smoking is not associated with a poorer response to TCZ in RA. . The presence of RF or ACPA is not predictive of a good response to TCZ therapy in RA. 
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